February 25, 2026 – Raleigh, North Carolina & Tel-Aviv, Israel
RedHill Biopharma Ltd. has announced the full operational and commercial launch of Talicia® in the United States under a joint commercialization agreement with Cumberland Pharmaceuticals through their jointly controlled entity, Talicia Holdings Inc. The initiative marks the formal rollout of a coordinated commercialization model designed to accelerate market penetration and expand patient access to the therapy. Talicia®, an FDA-approved treatment for Helicobacter pylori (H. pylori) infection, is recognized as the only all-in-one, low-dose rifabutin-based therapy developed to address rising antibiotic resistance in first-line eradication treatment. The collaboration integrates sales, marketing, and operational infrastructure to maximize prescription growth and therapeutic reach across the U.S. gastroenterology market.
Joint Commercial Strategy Targets Market Expansion
The commercialization program is being executed through Talicia Holdings Inc., a co-managed operating entity structured to oversee market launch activities, physician engagement, and distribution strategy. The partnership combines RedHill’s gastrointestinal therapeutic expertise with Cumberland’s commercial infrastructure to strengthen field deployment and healthcare provider outreach.
The initiative is focused on unlocking the full market potential of Talicia®, currently the #1 branded gastroenterologist-prescribed therapy for H. pylori infection in the United States. By aligning operational resources and expanding promotional channels, the collaboration aims to improve prescribing adoption and optimize treatment accessibility for patients diagnosed with the bacterial infection.
Addressing Antibiotic Resistance in H. pylori Treatment
Advertisement
H. pylori infection remains one of the most prevalent chronic bacterial infections globally, affecting approximately 35% of the U.S. adult population, with an estimated 1.6 million patients receiving treatment annually. The pathogen is classified as a Group 1 carcinogen and is strongly associated with gastric cancer, peptic ulcer disease, and mucosa-associated lymphoid tissue lymphoma.
Talicia® was specifically developed to address increasing antibiotic resistance that has reduced the effectiveness of conventional eradication regimens. The therapy combines omeprazole, amoxicillin, and rifabutin in a fixed-dose oral capsule, providing a simplified all-in-one dosing approach. Its rifabutin-based mechanism is designed to overcome resistance patterns commonly seen with clarithromycin-based therapies.
Clinical guidelines from leading gastroenterology bodies recognize optimized 14-day regimens such as Talicia® as effective first-line treatment options intended to maximize eradication success and reduce the need for salvage therapy.
Regulatory Status and Global Growth Outlook
Talicia® received FDA approval for the treatment of H. pylori infection in adults and has been granted Qualified Infectious Disease Product (QIDP) designation, providing extended U.S. market exclusivity. Patent protection for the therapy extends through 2042, supporting long-term commercial positioning.
Beyond the United States, RedHill is pursuing broader international expansion strategies, including potential market entry initiatives in Europe and the Middle East. These efforts are aligned with the company’s objective to increase global patient access while securing additional licensing and commercialization partnerships.
The U.S. commercialization launch represents a significant milestone in RedHill’s gastrointestinal infectious disease portfolio, reinforcing its focus on therapies addressing antimicrobial resistance and complex bacterial infections. Through integrated commercial execution and targeted physician engagement, the partnership aims to ensure that more patients benefit from advanced eradication treatments designed for first-attempt cure success.
Source: RedHill Biopharma press release
